Cancer Research Institute
Clinical Trials
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
The main goal is to test any good and bad effects of the study drug olaparib on your tumor. A second goal of the study is to evaluate side effects that might be caused by olaparib and to learn more about the pharmacology (how y ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
The main goal of this study is to test any good and bad effects of the palbociclib on your tumor. A second goal of the study is to evaluate side effects that might be caused by palbociclib.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate)in Patients with Tumors Harboring Activating MAPK Pathway Mutations
The main goal is to test any good and bad effects of the study drug selumetinib (AZD6244 hydrogen sulfate) on your tumor. A second goal of the study is to evaluate side effects that might be caused by selumetinib (AZD6244 hydro ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations
This is a Phase 2 study of a study drug called tipifarnib. The main goal of the study is to find out what effect, good and/or bad effects the study drug tipifarnib may have on your tumor. A second goal of the study is to evalua ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring BRAF V600 Mutations
You are being asked to participate in this study because you have relapsed or refractory tumor without a proven treatment strategy for cure. The main goal is to test any good and bad effects of the study drug vemurafenib on you ...
Optune Lua for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used concurrently with pemetrexed and platinum-based chemotherapy
Optune Lua is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (“MPM”) to be used concurrently with pemetrexed and platinum-based chemotherapy. ...
PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of TTFields together with standard chemotherapy (gemcitabine and nab-paclitaxel) compared to standard chemotherapy (gemcitabine and nab-paclitaxel) without TTFiel ...
PD-L1 expression in lung adenocarcinomas with different subtypes of KRAS mutations and its clinical significance
The purpose of this study is to evaluate if the degree of PD-L1 expression and/or certain subtype(s) of KRAS mutation which may impact outcomes (survivals and/or pattern of metastasis) of lung adenocarcinoma. This may help det ...
Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
A medical research study for participants who have been diagnosed with a solid tumor (i.e. cancer) and currently, the tumor is unresponsive to approved treatments, approved treatments are worsening the symptoms or the participa ...